Capecitabine pills plus pyrotinib for advanced HER2 breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two oral drugs—capecitabine (a chemotherapy pill) and pyrotinib (a targeted therapy)—for people with HER2-positive breast cancer that has spread. It is for those who have already had a recent type of targeted therapy called an ADC and are looking for a new treatment option that does not require a hospital visit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have HER2-positive breast cancer that has spread to other parts of the body.
- You have already tried an antibody-drug conjugate (ADC) treatment for advanced cancer, and either your cancer got worse or you stopped it for side effects, cost, or personal choice.
- You have not taken a TKI or capecitabine (Xeloda) before for advanced cancer.
- Your doctor confirms you are in generally good health (ECOG 0-2) and your organs are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether taking pyrotinib (a daily pill) with capecitabine (another pill) after breast cancer surgery can help prevent HER2-positive early-stage breast cancer from coming back. It is for women who have already had their cancer removed and meet certain risk criteria.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a lower dose of the chemotherapy drug capecitabine in people with advanced breast cancer that is HER2 negative. It aims to see if this gentler dose works well, especially for older or frailer patients who may have more difficulty with standard treatment.
This trial tests whether adjusting the dose of the oral chemotherapy capecitabine over time can control metastatic breast cancer that is estrogen-receptor positive (ER+) and HER2−. It is designed for patients who are starting capecitabine or have just started it, and the study will monitor blood changes and tumor response closely.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This trial tests a targeted drug called pyrotinib for women with HER2-positive early or locally advanced breast cancer. It aims to see if adding this treatment before surgery improves outcomes.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.